EVAX Stock Summary and Trading Ideas (Evaxion A/S - American Depositary Share | NASDAQ:EVAX)

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Evaxion A/S - American Depositary Share trades on the NASDAQ stock market under the symbol EVAX.

As of November 9, 2026, EVAX stock price declined to $2.75 with 103,979 million shares trading.

EVAX has a beta of 1.33, meaning it tends to be more sensitive to market movements. EVAX has a correlation of 0.04 to the broad based SPY ETF.

EVAX has a market cap of $25.36 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, EVAX traded as high as $340.25 and as low as $1.20.

EVAX has underperformed the market in the last year with a price return of -56.1% while the SPY ETF gained +13.4%. EVAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.2% and -26.9%, respectively, while the SPY returned -1.8% and -1.0%, respectively.

EVAX support price is $2.78 and resistance is $3.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVAX shares will trade within this expected range on the day.